BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña LDL, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. European Journal of Cancer 2019;118:1-9. [DOI: 10.1016/j.ejca.2019.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Rybinska I, Sandri M, Bianchi F, Orlandi R, De Cecco L, Gasparini P, Campiglio M, Paolini B, Sfondrini L, Tagliabue E, Triulzi T. Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. Cells 2020;9:E434. [PMID: 32069815 DOI: 10.3390/cells9020434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Testa U, Castelli G, Pelosi E. Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Med Sci (Basel) 2020;8:E18. [PMID: 32210163 DOI: 10.3390/medsci8010018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
3 Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El‐abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV. What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine. [DOI: 10.1002/cam4.4449] [Reference Citation Analysis]
4 Swain SM, Tang G, Brauer HA, Goerlitz DS, Lucas PC, Robidoux A, Harris BT, Bandos H, Ren Y, Geyer CE Jr, Rastogi P, Mamounas EP, Wolmark N. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clin Cancer Res 2020;26:4233-41. [PMID: 32371537 DOI: 10.1158/1078-0432.CCR-20-0152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol Oncol 2021. [PMID: 34816585 DOI: 10.1002/1878-0261.13141] [Reference Citation Analysis]
6 Chica-Parrado MR, Godoy-Ortiz A, Jiménez B, Ribelles N, Barragan I, Alba E. Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers (Basel) 2020;12:E2012. [PMID: 32708049 DOI: 10.3390/cancers12082012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Jia L, Ling Y, Li K, Zhang L, Wang Y, Kang H. A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer. Clin Breast Cancer 2021:S1526-8209(21)00088-4. [PMID: 34052107 DOI: 10.1016/j.clbc.2021.04.010] [Reference Citation Analysis]